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Abstract
Variability in cell-to-cell behavior within clonal populations can be attributed to the inherent stochasticity of biochemical
reactions. Most single-cell studies have examined variation in behavior due to randomness in gene transcription. Here we
investigate the mechanism of cell fate choice and the origin of cell-to-cell variation during mitotic arrest, when transcription
is silenced. Prolonged mitotic arrest is commonly observed in cells treated with anti-mitotic drugs. Cell fate during mitotic
arrest is determined by two alternative pathways, one promoting cell death, the other promoting cyclin B1 degradation,
which leads to mitotic slippage and survival. It has been unclear whether these pathways are mechanistically coupled or
independent. In this study we experimentally uncoupled these two pathways using zVAD-fmk to block cell death or Cdc20
knockdown to block slippage. We then used time-lapse imaging to score the kinetics of single cells adopting the remaining
fate. We also used kinetic simulation to test whether the behaviors of death versus slippage in cell populations where both
pathways are active can be quantitatively recapitulated by a model that assumes stochastic competition between the
pathways. Our data are well fit by a model where the two pathways are mechanistically independent, and cell fate is
determined by a stochastic kinetic competition between them that results in cell-to-cell variation.
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Introduction
Individual cells choose between alternative states in many
aspects of biology. In most cases that have been investigated, the
decision is made by gene regulation. Single-cell studies on
randomness in mRNA transcription show that stochastic gene
expression plays a crucial role in bacterial competence, microbial
survival and blood cell differentiation [1–3]. Here, we investigate
how cells choose between alternative fates during mitotic arrest
induced by anti-mitotic drugs, where transcription is silenced due
to chromosome condensation, and decision-making must occur by
purely post-transcriptional mechanisms. Understanding how cells
chose between survival and death in response to a therapeutically
important drug class may help improve cancer chemotherapy.
One common cancer chemo-therapeutic strategy is to perturb
cell division with anti-mitotic drugs. Anti-mitotic drugs that target
microtubules (Taxanes, Vinca Alkaloids) are mainstays of current
chemotherapy, and new classes of anti-mitotics that specifically
interfere with the assembly of bipolar mitotic spindles by inhibiting
various mitotic kinases or kinesin motor proteins are under
development [4]. The primary targets of these drug classes differ,
but their cellular effects converge on disrupting mitotic spindle
assembly, leading to chronic failure to satisfy the spindle assembly
checkpoint (SAC). As a result, the cell cycle stalls in mitotic arrest
that lasts many hours. Some fraction of dividing cancer cells are
killed during or after this mitotic arrest, but typically not 100%.
Incomplete cell killing could be a problem for therapy, and its
mechanistic origin has been unclear. Recent single-cell studies
have shed light on variability in the drug response. In all cell lines
that have been studied, saturating drug concentrations causes
long-lasting mitotic arrest in 100% of the population. However,
subsequent behaviors vary profoundly. Individual cells may die
during the mitotic arrest, or slip out of the arrest into a tetraploid
G1 state, from which they may die, arrest in G1, or continue the
cell cycle [5–12]. Variation in cell fate was observed both as a
difference in individual cell behavior within a clonal population
(intra-cell line variation) and also as a difference in average
behavior between different cell lines (inter-cell line variation)
(Fig. 1A). It prompts the question, what kind of internal calculation
determines whether a given cell lives and slips or dies following
mitotic arrest, and why do individual cells vary in the result of this
calculation?
We know that cell fate during mitotic arrest is controlled by two
alternative pathways, one that promotes slippage out of mitosis
and cellular survival from mitotic stress, the other that promotes
cell death [13]. Mitotic slippage occurs because cyclin B1 is slowly
and progressively proteolyzed during mitotic arrest by the same
APC/C proteosome pathway that promotes normal mitotic exit
when the SAC is satisfied [14]. Eventually, cyclin B1 drops to a
low enough level that the cell can no longer sustain the mitotic
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slippage pathway, the pathway that triggers cell death in mitotic
arrest is less clear. It culminates in mitochondrial outer membrane
permeabilization (MOMP) and activation of capsases 9, 3 and 7.
The events that precede MOMP are not well understood; we and
others hypothesize that some progressive biochemical or organi-
zational change accumulates over hours during mitotic arrest,
eventually triggering MOMP [6,15–17]. This is analogous to the
signaling through slow accumulation of active Caspase-8 that
occurs during the extrinsic apoptosis pathway [18]. Based on this
understanding, Gascoigne and Taylor proposed a pathway
competition model to explain how cancer cells vary in fate
following mitotic arrest. They hypothesized that cyclin B1
degradation and accumulation of the pro-death signal occur
simultaneously, and that their outcomes are mutually exclusive.
Cells that slip out of mitosis cease producing the pro-death signal
and survive the mitotic arrest, whereas cells that initiate MOMP
before they exit mitosis are committed to die [7]. Whether a cell
slips and survives or dies in mitosis is determined by the relative
rates of the two pathways, which can vary in individual cells.
An important question yet to be resolved is whether the two
pathways are independent or mechanistically coupled when they
compete for cell fates during prolonged mitosis (Figure 1B).
Gascoigne and Taylor proposed the independent pathway model
by showing that the fraction of cells that slip or die can be altered
by perturbing the kinetics of either pathway [7]. The fact that we
were able to trigger cell death by blocking slippage with Cdc20
siRNA in our previous study also suggests that slippage and death
pathways are mechanistically independent to a certain degree [9].
However, these studies did not rule out the possibility that there
may be crosstalk between the signaling pathways. Previous reports
in the literature suggest at least two possible ways that the two
pathways could be cross-linked. Kim et al proposed that the death
pathway directly promotes slippage, by caspase-dependent prote-
olysis of the SAC protein BubR1 [19]. Allan and Clark showed
that Caspase 9 is phosphorylated and inactivated by Cdk1/cyclin
B1 in mitosis [20]. They thus proposed that gradual degradation of
cyclin B1 resulted in gradual activation of caspase 9. Such crosstalk
between the pathways may not be strong enough to completely
activate/inactivate the pathway, but it may very well accelerate/
delay its kinetics. In this study, we sought to investigate the kinetic
interdependence of the two pathways and quantitatively distin-
guish between the independent and coupled pathway models by
single-cell time-lapse experiments and simulations.
To investigate interdependence of the death and slippage
pathways, we chose four cancer-derived cell lines from a larger
panel we previously profiled [6] to span the full range of death-
sensitivity in response to anti-mitotic drugs, including HeLa,
MDA-MB-435S, A549 and MCF7 (listed in descending order of
death sensitivity). We used a Kinesin-5 inhibitor (K5I),
EMD534085, to induce mitotic arrest, as the action of this drug
is specific to mitosis, unlike paclitaxel which also perturbs
interphase microtubules. Kinesin-5 inhibitors promote cell death
mainly during mitotic arrest, whereas paclitaxel promotes also
high level of death after slippage [6,9]. This may make paclitaxel
more clinically active, but it would complicate our study, where we
wish to focus on decision-making during mitotic arrest exclusively.
We have seen very similar responses to EMD534085 and s-trityl-
cysteine, a commercially available Kinesin-5 inhibitor [8].
Results
Kinetics of mitotic slippage in the absence of cell death
To measure kinetics of mitotic slippage without the presence of
cell death, we used a broad spectrum caspase inhibitor, zVAD-
fmk, to block caspase activity. This treatment blocked cell death in
.90% of cells in all lines over the duration of our experiments,
which allowed us to test pathway interdependence. Since this drug
Figure 1. Kinetic models explaining intra- and inter-line variations. (A) Intra- and inter-line variations under the same drug stimuli. For intra-
line variation, non-genetic variations in protein levels or post-translational modifications among individual cells results in different cell fates within a
clonal population. For inter-line variation, the average behavior, or overall percentage of cell death/survival, is determined by genetic factors. (B)
Models of kinetic competition between death and slippage. For independent pathway competition, mitotic state triggers two independent
processes, caspase activation and cyclin B1 proteolysis, each leading to its corresponding state. For coupled pathway competition, mitotic states
triggers one signal that is triggering the other, and the two coupled processes compete with their kinetic rates. M: mitosis; D: death; G1: post-slippage
G1.
doi:10.1371/journal.pone.0015724.g001
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different pathways that we do not consider in our model. We
scored the time interval between mitotic entry and slippage in
unsynchronized populations using time-lapse phase-contrast
imaging as described [8,9]. Figure S1 showed representative
time-series images of HeLa and A549 cells treated with K5I. From
the single-cell movies, probability distributions of duration of
mitotic arrest were quantified and results were shown for the four
chosen cell lines in Figure 2A. In all cases, 100% of cells scored
eventually slipped out of mitosis. Average arrest durations were:
HeLa 28.4 hr, MDA-MB-435S 30.4 hr, MCF7 12.4 hr, A549
18.6 hr. The shape of the distributions appeared approximately
normal in each case, with the shortest duration of mitotic exit
much larger than zero. This distribution is consistent with the
previously proposed ramp-threshold model for slippage kinetics
[5]: at the time of mitotic entry, level of cyclin B1 starts to decrease
(i.e. ramp down) with approximately linear kinetics, until it drops
below a threshold that is required to sustain mitotic arrest [7,9].
Variance in the observed population distribution of arrest time was
probably resulted from variation in cyclin B1 degradation rate, or
starting concentration, in individual cells.
Less than 10% A549 cells undergo cell death during mitotic
arrest in K5I alone, so we could directly compare the duration of
arrest with and without zVAD-fmk to test for pathway
dependence. The distributions of arrest duration were very similar
(Fig. 2B) and a statistical test failed to show a significant difference
between them (p=0.42). This observation strongly negates models
in which slippage depends on caspase activation [19], and is
consistent with the independent pathway model. A simple
comparison of slippage kinetics +/2 zVAD-fmk cannot be made
across the whole population in more death-sensitive lines because
many cells die during mitotic arrest in K5I alone. However, we
can compare slippage kinetics for the fraction of cells that do not
die in drug alone. Figure 2C showed this comparison for HeLa
cells, of which ,10% of cells survive mitotic arrest in K5I alone.
Comparison of this minority population in K5I alone with the
whole population in K5I + zVAD-fmk showed very similar
distributions of mitotic arrest duration (p=0.43), again arguing for
pathway independence.
Cyclin B1 degradation kinetics are insensitive to
perturbation of the death pathway
Another way to test for pathway interdependence is to
accelerate one pathway, and look for effects on kinetics of the
other. This is possible for the cell death pathway by adding an
additional pro-death signal that converges with the pro-death
pathway activated by mitotic arrest. We added TRAIL (tumor
necrosis factor (TNF)-related apoptosis-inducing ligand) as the
additional pro-death signal. TRAIL activates the extrinsic death
pathway, which converges on the intrinsic pathway at the level of
triggering MOMP and/or by directly activating Caspase 3 [21].
We empirically determined a TRAIL concentration sufficient to
speed up cell death in mitosis, but insufficient to trigger rapid
death in interphase. Because cells died faster in mitosis when
TRAIL was added, we could not use mitotic exit to monitor the
Figure 2. Slippage kinetics under perturbation of cell death. (A) Probability distributions of time duration from mitotic entry to exit for four
cell lines treated with Kinesin-5 inhibitor (K5I) and zVAD-fmk. Numbers in parentheses indicate number of cells scored. (B) Probability distributions of
time duration from mitotic entry to exit in A549 cells treated with K5I alone (blue) or K5I plus zVAD-fmk (green). Numbers in parentheses indicate
number of cells scored. (C) Probability distributions of time duration from mitotic entry to exit in HeLa cells treated with K5I alone (blue) or K5I plus
zVAD-fmk (green). Only cells that exited mitosis were scored for both treatments (for K5I alone: less than 10%; with zVAD-fmk: more than 90%).
Numbers in parentheses indicate number of cells scored. (D) Four representative cyclin B1 degradation curves before and after the addition of TRAIL
in HeLa cells treated with K5I. Average of whole-cell fluorescent intensity was measured using Region Statistics function in MetaMorph. Degradation
rates before and after TRAIL addition were calculated using Linear Regression function in GraphPad Prism 4.
doi:10.1371/journal.pone.0015724.g002
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directly, by infecting HeLa cells with adenovirus expressing full-
length cyclin B1 fused to EGFP [22]. We chose to express this
exogenous cyclin B1 reporter at a level close to the endogenous
cyclin B1 (Fig. S2A, 1:100) so the amount of total cyclin B1 was
roughly 2-fold of the endogenous level in all our experiments.
Cyclin B1 levels were monitored in real time by time-lapse
fluorescence microscopy. K5I was added at the start of the
imaging experiment. After the majority of cells had entered mitosis
(judged by cell rounding), TRAIL was added to accelerate caspase
activation and cell death. The average time from mitotic entry to
death was 11.6 hr when TRAIL was added, significantly shorter
than the death time of 18.0 hr for K5I treatment alone.
Figure 2D showed four representative single-cell fluorescence
trajectories of EGFP-cyclin B1. Fluorescence of this cyclin B1
reporter, which is proportional to its concentration, decreased
roughly linearly in time in mitotic arrest as previously reported [9].
After TRAIL addition, cyclin B1 continued to decrease linearly,
with a rate that appeared to be not significantly different from that
without TRAIL. In order to quantify the rate change of cyclin B1
degradation instead of relying on visual inspection of the traces, we
calculated the normalized rate change for every individual cell,
defined as (|kb|-|ka|)/|ka|, where ka and kb are cyclin B1
degradation rates before and after TRAIL addition (note that we
assumed linear, not exponential, degradation kinetics in estimating
these rates from the data). For the 27 cells that we analyzed, cyclin
B1 degradation may be both slightly accelerated (12 out 27) and
decelerated (15 out of 27) after TRAIL addition. Population
average of the normalized rate change was calculated to be
0.1160.59, suggesting the rate of cyclin B1 degradation on
average increased by 11% after TRAIL addition. We considered
such change was relatively small. Together with the observation
that TRAIL addition may both accelerate and decelerate cyclin
B1 degradation in individual cells, i.e. it triggers no universal
trend, we conclude that addition of TRAIL did not alter kinetics of
cyclin degradation, or mitotic exit.
We also measured, at the ensemble level, degradation kinetics of
endogenous cyclin B1 in mitotic arrest with and without zVAD-
fmk using western blotting. To conduct the experiment in mitotic-
arrest cells, we treated HeLa cells with K5I for 3 hours, gently
shook off the mitotic fraction of cells, then continued to culture
cells in K5I or K5I + zVAD-fmk. Time series of cell lysates were
obtained to perform immunoblots. As shown in figure S2B, along
with quantification of the blot in figure S2C, inhibition of cell
death in mitosis by zVAD-fmk did not alter the degradation
kinetics of endogenous cyclin B1, further supporting the model
that these two pathways are independent. In summary, our data all
point to pathway independence, in which perturbation of the
death pathway by either inhibition with zVAD-fmk or super-
activation with TRAIL did not affect kinetics of mitotic slippage.
Kinetics of cell death in the absence of mitotic slippage
To measure kinetics of cell death without the presence of mitotic
slippage, we knocked down Cdc20 by siRNA treatment to block
cyclin B1 proteolysis. We showed previously that this treatment is
effective and specific, though it is important to control for some
non-specific toxicity of the transfection protocol using control
siRNA treatment [9]. We again scored the time interval between
mitotic entry and cell death in unsynchronized populations using
time-lapse phase-contrast imaging. Following Cdc20 siRNA
treatment, 100% of cells died during mitotic arrest in all four
cell lines and none slipped, indicating we had completely blocked
the slippage pathway, and thus eliminated intra-cell line variation
in fate choice. Figure 3A reported the population distributions of
time between mitotic entry and death for the four lines. Average
times for induction of death were: HeLa 18.0 hr, MDA-MB-435S
Figure 3. Death kinetics under perturbation of mitotic slippage. (A) Probability distributions of time duration from mitotic entry to death for
four cell lines treated with Cdc20 siRNA and K5I. Numbers in parentheses indicate number of cells scored. (B) Probability distributions of time
duration from mitotic entry to death under K5I plus Lamin A/C siRNA (blue) or Cdc20 siRNA (green). Only cells that died in mitosis were scored for K5I
treatment (for HeLa: 90.3%, for MDA: 77.3%, (9)). Only the corresponding percentages of early mitotic death events were scored for Cdc20 siRNA
treatment. Numbers in parentheses indicate number of cells scored.
doi:10.1371/journal.pone.0015724.g003
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broad, reflecting high intra-cell line variation in death kinetics.
The left side of each histogram had a large distance from zero,
consistent with a ramp-threshold model for the kinetics of the pro-
death pathway, similar to those of the slippage pathway, except
that we do not know the identity of the molecule(s) that changes
over time.
We reported previously that in the most death-sensitive line,
HeLa, blocking slippage had little effect on death kinetics [9].
Here, we re-plotted the fraction of cells that died in mitosis under
K5I, and the corresponding percentage of early mitotic death
events under Cdc20 knockdown, as probability distributions, for
HeLa and MDA-MB-435S. Death in mitosis is the dominant cell
fate for these two death-sensitive cell lines, thus allowing
quantification of sufficient dead cells for such statistical analysis.
Distributions of time from mitotic arrest to death were similar
under both K5I and Cdc20 RNAi for the two lines, as the
calculated p values under the two conditions were not statistically
significant (i.e. HeLa: p=0.24; MDA-MB-435S: p=0.78). This
suggests loss of the slippage pathway did not affect death kinetics.
The same kinetic comparisons for MCF-7 and A549 were re-
plotted as survival curves in supplementary figure S3. It is evident
that the initial drop in the curves, which corresponds to cell death
in mitosis, showed similar kinetics under both K5I and Cdc20
RNAi. We chose to show the kinetics as survival curves instead of
probability distributions for MCF7 and A549, as these two cell
lines are death-resistant so death in mitosis is a rare event and we
did not have enough data to generate the probability distribution
curves. All the above experimental data showed kinetics of cell
death were not perturbed by inhibition of mitotic slippage, again
supporting a kinetic model of pathway independence.
Simulation of single-cell statistics of mitotic cell fate
One limitation of the pathway perturbation approaches in
Figures 2 and 3 is that we can only directly compare kinetics of one
pathway in the presence vs. in the absence of the other when that
pathway dominates kinetically, i.e. for slippage in A549 and death
in HeLa. In other cases, the kinetically dominant pathway
precludes measurement of the alternative pathway, except in a
small fraction of cells that choose that fate (e.g. slippage in HeLa
shown in Fig. 2C). We therefore turned to a simple simulation
strategy to test models of different kinetic interdependence of the
two pathways when both are operational. For simulation, we first
re-plotted the lifetime distributions when only one pathway was
functional while the other was blocked (Fig. 2A and 3A) in the
form of cumulative distribution functions, which showed the
fraction of cells that had either died or slipped as a function of time
after entering mitotic arrest (Fig. 4A). Visual inspection of these
plots already reveals general trends: in death-sensitive cell lines
(HeLa and MDA-MB-435S), death typically occurs before
slippage; while in death-resistant cell lines (MCF7 and A549),
the reverse is true.
To simulate a given cell’s behavior quantitatively, we randomly
sampled times of mitotic death and slippage from the two one-
pathway cumulative distributions. We scored a cell as dying or
slipping depending on which event occurred first, and the time of
the event was determined by the shorter time. We chose to
simulate two distinct scenarios: kinetic competition of independent
or coupled pathways. For simulation of independent pathway
competition, mitotic death and slippage events were randomly and
independently generated from their respective cumulative distri-
butions. 100 single-cell events were generated per simulation. For
each of the four cell lines we studied, several simulated survival
Figure 4. Simulations assuming independent or coupled pathway competition. (A) Cumulative distribution functions of mitotic death
(blue) and slippage (green) for four cell lines from experimental measurement. (B) Cumulative survival curves for independent (blue) and coupled
(green) pathway competition, averaged over ten sets of simulated data (each consist of 100 single-cell events). The corresponding experimental
curve is shown in black.
doi:10.1371/journal.pone.0015724.g004
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K5I alone, where both pathways are active (Fig. S4). In general,
we saw good agreement between simulated (averaged over 10 sets
of simulations) and experimental data, though the simulation
slightly under-estimated the final percentage of cell death in MDA-
MB-435S and MCF7 (Fig. 4B, blue lines). For simulation of
kinetically correlated pathway competition, mitotic death and
slippage events were chosen in a correlated fashion. For example,
if mitotic death event was first randomly generated, the
corresponding slippage event was then specifically chosen from
the cumulative distribution at a time duration region similar to the
mitotic event, and vice versa. As shown in the green lines of
Figure 4, simulation results of the correlated pathway model
significantly over-estimated death in HeLa and MDA-MB-435S
and failed to predict any death events in MCF7 and A549.
Therefore, a kinetic model of stochastic competition between
independent pathways appeared to better explain our experimen-
tal observations.
Discussion
In this paper, we used experimental perturbation and kinetic
simulation to test whether the two cell fate-determining processes
induced by mitotic arrest, i.e. mitotic death and mitotic slippage,
occur by pathwaysthat are,orare not,mechanisticallycoupled and/
or kinetically correlated. Our data of slippage kinetics when death
was blocked, and death kinetics when slippage was blocked (Fig. 2
and 3), argue against mechanistic coupling. A stronger and more
quantitative test of the mechanistic independence is to ask if the
kinetics of one pathway are altered by blocking or accelerating the
other. We could make these direct comparisons only experimentally
for death in the death-sensitive lines, and slippage in the death-
resistant lines. Indeed, the kinetics of one pathway were unaffected
by blocking the other in these cases (Fig. 2B and 3B). A direct
comparison of kinetics with and without blocking the alternative
pathway was more generally possible for the small subset of cells that
undergo the less prevalent pathway when both are operational.
Again, we observed no effectof blocking one pathwayon the kinetics
of the other, but this is a weaker test, since it includes only a subset of
cells that might not be typical. In addition, we also observed that
accelerating caspase activation had no effect on the kinetics of cyclin
B1 proteolysis in single cells (Fig. 2D), further substantiating the
independence of the slippage and death pathways.
A subtler test of pathway independence is to ask if two pathways
are kinetically correlated in individual cells. Kinetic correlation is
likely if pathways share upstream events, but could occur for other
reasons, for example if the kinetics of both pathways depend on
some common external variables, such as cell size, protein
synthesis rate etc. We approached this question using kinetic
simulation, asking how well the rates of each pathway alone,
measured when the other is blocked, predict cell behavior when
both pathways are active. We observed a good fit of simulated to
experimental data assuming uncorrelated kinetics (Fig. 4B). A
simulation of correlated kinetics fit the data less well in all the cell
lines, though the distinction is not sufficiently large to completely
rule out some degree of kinetic correlation. Overall, our
observations strongly favor the independent pathway model in
Figure 1B. We conclude that the large inter- and intra-cell line
variability in response to anti-mitotic drugs is due to stochastic
competition between two mechanistically and kinetically indepen-
dent pathways, both of whose kinetics can be approximated by a
gradual change in some parameter until a threshold is crossed,
subsequently triggering an irreversible change that blocks the
other pathway. In the exit pathway the gradual change is in Cyclin
B concentration, in the death pathway its biochemistry is not yet
known.
An interesting consequence of independent pathway competi-
tion is that fairly small changes in kinetics of either pathway can
cause large changes in average cell fate. Average time for
execution of the slippage and death pathways both varied ,2.5
fold across the 4 cell lines that we studied. However, this relatively
small rate difference is enough that in a cell line where death is
faster than slippage, .90% of cells die during mitotic arrest
(HeLa), while in a cell line where slippage is faster than death,
,10% of cells die (MCF7 and A549). Large variation in average
cell fate despite relatively small variation in pathway may explain
why the cell death response to anti-mitotic drugs varies strongly
across cancer cell lines [6], and why individual cells within a line
can exhibit different fates. It may contribute to response variation
in anti-mitotics seen in the clinic [23], and might also help explain
why clinical resistance seems to arise rapidly to current anti-cancer
drugs, including anti-mitotics.
So what is the mechanistic source of the rate variation we
observe? We know from experimental measurements that most
proteins vary up to 2-fold in concentration between individual cells
in clonal populations of human cancer cells in culture, presumably
due to stochasticity in gene expression and protein degradation
[24]. Spencer et al argued that this kind of variation is sufficient to
explain intra-line variation in response to TRAIL [25]. In the case
that we study, noise in protein degradation and protein
phosphorylation are likely to be key factors in causing cell-to-cell
variation, as mitosis is a hyper-phosphorylated state where
transcription is silenced and translation significantly attenuated.
Protein degradation rate is known to control slippage kinetics [10].
It might also control the kinetics of apoptosis activation, though
since our data favors uncorrelated kinetics for the two pathways, it
would likely be proteolysis regulated in a different way. Cell-to-cell
variation in proteolysis rates is an important topic for future
research.
Many studies have revealed variation in sensitivity to apoptosis
between cancer cell lines and investigated their origins [26], and it
is easy to imagine that cancer clones are selected for decreased
apoptosis sensitivity. Perhaps surprisingly, we observed just as
much inter-cell line variation in slippage rates as we did in
apoptosis rates (,2.5 fold in both cases), though we know of no
reason drug-naı ¨ve cancer cells should be selected for altered
slippage rates. Could this degree of variation in average rate
between clonal cell lines be typical for complex cellular pathways?
Our study, along with other recent work [25], shows that intra-line
variation in pathway rates can cause significant variation in cell
fate in response to drug, which presumably contributes to the
difficulty of completely eradicating cancer using drug treatments.
Materials and Methods
Cell culture and virus
All cell lines were purchased from American Type Culture
Collection (ATCC, USA) and cultured under 37uC and 5% CO2
in appropriate medium supplemented with 10% fetal calf serum
(FCS), 100 U/ml penicillin and 100 mg/ml streptomycin. HeLa
and MDA-MB-435S were maintained in DMEM; MCF7 was
maintained in RPMI; A549 was maintained in F-12K. Adenovirus
expressing full-length cyclin-B1-EGFP was a gift from Randy King
(Harvard Medical School).
Chemicals and siRNA
Pan-caspase inhibitor, zVAD-fmk was purchased from Calbio-
chem and used at 100 mM. A potent and selective Kinesin-5
Stochastic Competition Determines Cell Fate
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Killer TRAIL was a gift from Peter Sorger (Harvard Medical
School) and used at 0.1 ml/ml. To deplete Cdc20, Ambion
Silencer Select siRNA against Cdc20 (s2748) was used in all
experiments at a final concentration of 50–100 nM. Dharmacon
Lamin A/C siRNA duplex was used as control. siRNA
transfection was performed using HiPerFect (Qiagen) according
to manufacturer’s instructions.
Immunoblot Analysis
Cell lysates obtained using LDS sample buffer (NuPAGE,
Invitrogen) were resolved on 10% Tris-HEPES gels (Pierce) and
transferred to nitrocellulose membranes. Immunoblotting was
performed according to manufacturers’ recommendations using
enhanced chemiluminescence (Amersham). Antibodies against
cyclin B1 were purchased from BD Bioscience; PARP from Cell
Signaling; tubulin from Sigma.
Time-lapse imaging
Cells were seeded in glass-bottom plates (MatTek) in CO2-
independent medium (Invitrogen) supplemented with 10% FBS,
100 U/ml penicillin and 100 mg/ml streptomycin. For fluorescent
time-lapse imaging cells were seeded in phenol red-free CO2-
independent medium (Invitrogen). Image acquisition was per-
formed using Nikon TE2000 automated inverted microscope with
a2 0 6 objective enclosed in a humidified incubation chamber
maintained at 37uC. Images were collected every 15–30 min using
a motorized stage. Images were viewed and analyzed using
MetaMorph software (Molecular Devices).
Simulation of cell fate in mitosis
For simulation of independent pathways competition, two
independent random numbers (uniformly distributed between 0
and 1), one corresponding to death (RD) and the other
corresponding to slippage (RS), were generated using the Random
function in MATLAB. RD and RS were used to sample time from
mitotic entry to mitotic death (TD) and time from mitotic entry to
mitotic slippage (TS), respectively. The probability of observing a
mitotic death at time TD was given by RD =f D(TD), which was
the cumulative lifetime distribution function (discrete function with
bin size =2 hr) obtained from our experiments (Fig. 4A, blue
lines). Similarly, the probability of observing a mitotic slippage at
time TS was given by RS =f S(TS) (Fig. 4A, green lines). Now we
had two randomly generated TD and TS sampled from the
distribution functions, cell fate was then determined by the relative
value of TD and TS.I fT D , TS, meaning death occurs before
slippage, then this simulated event was scored as ‘‘death’’. On the
other hand, if TS , TD, meaning slippage happens before death,
this simulated event was scored as ‘‘slippage’’. For simulation of
coupled pathways competition, one random number (R) was
generated to sample both TD and TS. The probability of observing
a mitotic death at time TD and mitotic slippage at time TS were
given by R =f D(TD) and R =f S(TS), respectively. Cell fate is
again determined by the relative value of TD and TS.
Supporting Information
Figure S1 Time sequence of phase-contrast images of HeLa and
A549 cells under K5I treatment. Numbers show elapsed time
(hour:minute) relative to mitotic entry.
(TIF)
Figure S2 Analysis of cyclin B1 level by immunoblotting. (A)
Comparison of endogenous (60 KDa) and exogenous (87 KDa)
cyclin B1 level. HeLa cells were infected by adenovirus expressing
full-length cyclin-B1-EGFP with indicated adenovirus-to-media
ratio. Cell lysates were collected for immunoblots of cyclin B1 and
tubulin (loading control). (B) Cyclin B1 degradation kinetics under
K5I or K5I plus zVAD-fmk analyzed by immunoblotting. HeLa
cells were treated with K5I for 3 hours, and mitotic fraction were
shaken off and continued to be cultured in K5I or K5I plus zVAD-
fmk with indicated times. Time series lysates were collected for
immunoblot of PARP, cyclin B1 and tubulin. (C) Quantification of
cyclin B1 degradation kinetics from (B). Area and mean intensity
of inverted cyclin B1 bands were measured by ImageJ, and cyclin
B1 level was defined as area multiplied by mean intensity. Cyclin
B1 levels were normalized by the initial level (3 hours) and plotted
as a function of time since mitotic entry.
(TIF)
Figure S3 Cumulative survival curves for indicated treatments
in MCF7 and A549 (data from [9]).
(TIF)
Figure S4 Representative cumulative survival curves for simu-
lated independent pathway competition. Each line consists of 100
single-cell events. The corresponding experimental curves are
shown in black.
(TIF)
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